Old Web
English
Sign In
Acemap
>
authorDetail
>
Eusebio Manchado
Eusebio Manchado
Novartis
KRAS
Trametinib
MEK inhibitor
Cancer research
Cancer cell
3
Papers
36
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Brief Report: Phase I clinical trial of trametinib and ponatinib in patients with non-small cell lung cancer harboring KRAS mutations
2021
Kathryn C. Arbour
Eusebio Manchado
Matthew J. Bott
Linda Ahn
Yosef Tobi
Andy Ni
Helena A. Yu
Alyssa Shannon
Marc Ladanyi
Victoria Perron
Michelle S. Ginsberg
Amanda Johnson
Andrei I. Holodny
Mark G. Kris
Charles M. Rudin
Piro Lito
Neal Rosen
Scott W. Lowe
Gregory J. Riely
Show All
Source
Cite
Save
Citations (0)
Abstract A44: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors
2020
Molecular Cancer Research
Hengyu Lu
Chen Liu
Roberto Velazquez
Hongyun Wang
Lukas M. Dunkl
Malika Kazic-Legueux
Anne Haberkorn
Eric Billy
Eusebio Manchado
Saskia M. Brachmann
Susan E. Moody
Jeffrey A. Engelman
Peter S. Hammerman
Giordano Caponigro
Morvarid Mohseni
Huai-Xiang Hao
Show All
Source
Cite
Save
Citations (0)
SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors
2019
Molecular Cancer Therapeutics
Hengyu Lu
Chen Liu
Roberto Velazquez
Hongyun Wang
Lukas Manuel Dunkl
Malika Kazic-Legueux
Anne Haberkorn
Eric Billy
Eusebio Manchado
Saskia Brachmann
Susan E. Moody
Jeffrey A. Engelman
Peter S. Hammerman
Giordano Caponigro
Morvarid Mohseni
Huaixiang Hao
Show All
Source
Cite
Save
Citations (36)
1